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 ABSTRACT 
 
Introduction: ​Glioblastoma (GBM) is the most common malignant primary tumor of the            
central nervous system in the adult male. The average survival is between 3 and 5 months                
without treatment, and between 9 and 15 months with surgical resection accompanied by             
chemotherapy and radiotherapy. Discovering accurate prognostic markers is important for          
finding the optimal treatment strategy for each patient diagnosed with GBM. Objectives:            
Evaluate the correlation between the expression of Telomerase Reverse Transcriptase protein           
(TERT), the magnitude of peritumoral cerebral edema and outcome in patients to identify a              
possible prognostic factor for GBM. ​Methodology: Patients treated by the neurosurgery           
department of Hospital Santa Paula, São Paulo, Brazil, between 2010 and 2018 with a              
diagnosis of glioblastomas were selected. The patient data was collected from the patient             
journals. The size of the peritumoral cerebral edema was classified from the magnetic             
resonance. The tissue-samples were collected after the surgery, and were submitted to a             
histological and immunohistochemical analysis to evaluate the level of protein and gene            
expression of TERT. Due to the limited samples only descriptive statistics was used. ​Results:              
Out of the 12 patients, 4 had a positive protein expression of TERT and the older patients                 
generally showed a lower expression. Of the 5 deceased patients, all but one had major               
edema, and none showed any expression of TERT protein. In addition, all the patients with               
GBMs found in the parietal lobe died. ​Discussion: ​Lower levels of TERT may be related to                
advanced age. GBMs located in the parietal lobe may be more aggressive. There was a direct                
positive relationship between death and peritumoral edema, as well as a negative relationship             
between death and TERT protein expression, but the sample was too low for statistical              
significance to these conclusions.  
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 1. INTRODUCTION 
 
Glioma is a general term for primary brain tumors, and can be derived from various               
brain cells. Glioblastoma (GBM) originates from astrocytes and is the most common            
malignant tumor in the central nervous system. It accounts for about 15% of all intracranial               
brain tumors and 48% of all primary malignant CNS-tumors (Ostrom et. al. 2018), and for               
more than 60% of all the malignant brain tumors in adults (Rock et al., 2014). It affects more                  
men than women (1.5:1) and has a global incidence of less than 10 per 100,000. The primary                 
type affects more the elderly. It is diffuse, invasive, and very aggressive, and has a prognosis                
of only 3-5% 5-year survival rate and an average survival of 12 to 15 months with the                 
recommended multimodal treatment. The secondary type can affect people of a younger age             
and is associated with a higher rate of survival (Tamimi et al., 2017; Szopa et al., 2017; Yan                  
et al., 2009). 
 
Exposure to high levels of ionizing radiation normally used in radiotherapy is the only              
factor that has been confirmed to increase the risk of developing GBM. This does not include                
diagnostic radiation, and neither has typical environmental factors such as smoking, cell            
phone usage and pesticides shown an increased risk of GBMs. Heredity is not common and is                
only present in 5-10% (Prasad et al., 2009; Bondy et al., 2008; Inskip et al., 2001; Ohgaki,                 
2009; Agnihotri et al., 2013; Fisher et al., 2007). However, a meta-analysis showed that              
allergy can serve as a protective factor, perhaps because it is generally associated with an               
upregulated immune response (Linos et al., 2007). Patients with some genetic syndromes such             
as neurofibromatosis and tuberous sclerosis has shown a higher incidence of GBM (Johansson             
et. al. 2016). 
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 1.1 Site and Symptoms  
The majority, 95%, of GBMs are located in the supratentorial regions of the brain with               
a preference for the frontal lobe, followed by the temporal, parietal, and occipital lobes, and               
seldom find their way to the cerebellum or the brain stem (Nakada et al. 2011). General                
symptoms include intracranial hypertension, persistent headache, vomiting, papilledema,        
mental changes, and seizures, whereas the focal symptoms vary greatly depending on the             
region of the brain the tumor is located in and affects (Shapiro et al. 2011). A summary of the                   
specific symptoms associated to each lobe can be seen below in the table. 
Table 1: Symptoms related to location of brain tumor 
Location Associated Common Symptoms 
Frontal lobe Personality changes. 
Increased aggression or irritation. 
Apathy. 
Weakness on one side of the body. 
Loss of smell. 
Difficulty walking. 
Vision / Speech problems. 
Temporal 
lobe 
Forgetting words. 
Short-term memory loss. 
Seizures (often associated with strange smells/feelings). 
Parietal lobe Difficulty speaking / understanding. 
Problems reading / writing. 
Loss of feeling in part of the body. 
Occipital lobe Visual field deficits.  
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 1.2. WHO classification and Karnofsky Performance Status 
Prior to 2016, gliomas were classified by histological features such as cell atypia, the              
morphology of the cell nucleus, density of cells, number of mitosis, proliferation of blood              
vessels and tumor necrosis (Louis et. al, 2007). Since 2016, however, gliomas are classified              
by the World Health Organization (WHO) by a combination of histological features and             
genetic factors (or biomarkers) into grade I to IV depending on its malignancy. Grade I are                
considered curable with resection and grade II to IV are considered to be malignant and               
invasive. GBMs are classified grade IV Astrocytomas and can be primary tumors that arise              
de-novo (>90%) or secondary tumors that develop from low-grade gliomas (8%). They are             
further divided into GBM, IDH-wild type and GBM, IDH-mutant depending on whether a             
particularly important gene, ​isocitrate dehydrogenase (IDH) which is further discussed below,           
is mutated or not (Louis et. al, 2016). 
 
Karnofsky’s Performance Status (KPS) is an index that classifies the overall           
well-being of patients and can be used to identify high-risk patients, compare and choose              
different therapies and to assess the prognosis in individual patients (Crooks et. al, 1991). 
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 Table 2: Karnofsky’s Performance Status scale definitions rating (%) criteria. 
Able to carry on normal 
activity and to work; no 
special care needed. 
100% Normal no complaints; no evidence of disease. 
90% Able to carry on normal activity; minor signs or 
symptoms of disease. 
80% Normal activity with effort; some signs or symptoms 
of disease. 
Unable to work; able to 
live at home and care 
for most personal needs; 
varying amount of 
assistance needed. 
70% Cares for self; unable to carry on normal activity or to 
do active work. 
60% Requires occasional assistance but is able to care for 
most of his personal needs. 
50% Requires considerable assistance and frequent medical 
care. 
Unable to care for self; 
requires equivalent of 
institutional or hospital 
care; disease may be 
progressing rapidly. 
40% Disabled; requires special care and assistance. 
30% Severely disabled; hospital admission is indicated 
although death not imminent. 
20% Very sick; hospital admission necessary; active 
supportive treatment necessary. 
10% Moribund; fatal processes progressing rapidly. 
0% Dead 
 
 
1.3. Biomarkers 
Prognostic biomarkers are often genetic mutations and are of importance in           
determining the probable outcome, i.e. how likely the patient will suffer relapse, the             
progression of symptoms, the overall survival, and can serve as a tool for deciding therapeutic               
strategies for patients. (Pesenti et al., 2017; Szopa et al., 2017, Louis et al., 2016; Jovčevska et                 
al., 2013). They are seldom specific and can usually be found in a variety of cancers, but this                  
study will focus on the biomarkers that can say something about gliomas in general and               
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 glioblastomas in particular. Many are still being developed, and they can be divided into              
subgroups according to what type of function they fulfil in the cancerous cells, as described in                
the hallmarks of cancer (Hanahan et. al, 2011). A thorough review of the particular hallmarks               
of glioblastomas was done in a systematic review by Nørøxe et. al, 2016, and some of the                 
major ones that are frequently tested in routine clinical practice will be presented more in               
detail below. 
 
Figure 1: Hallmarks of cancer ​(from Hanahan et. al, 2011). 
 
 
A particularly important diagnostic biomarker for GBMs and related to the hallmark            
of “reprogramming cellular energetics” is the mutation of ​isocitrate dehydrogenase (IDH)           
enzymes 1 and 2. These are metabolic enzymes that have been found mutated in a wide range                 
of cancers such as acute myeloid leukemia (AML), cholangiocarcinoma, chondrosarcoma and           
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 glioma. Mutations in IDH decrease its normal activity and lowers the metabolism of the              
cancerous cells, which means that the growth is also impaired. These mutations are thus              
associated with better outcome in gliomas and serve as a prognostic biomarker (Derek et al.,               
2017).  
 
Another important biomarker, especially important for the selection of adjuvant          
chemotherapy, is the methylation of the promoter of the gene O6-methylguanine-DNA           
methyltransferase (MGMT). This gene codes for a DNA-repair protein that removes alkyl            
groups from guanine, which means that the GBM-cells that have high levels of MGMT are               
more resistant towards alkylating chemotherapeutic agents. Methylation of MGMT, however,          
silences the gene, and in such patients alkylating agents are much more efficient. (Stupp et. al,                
2005, 2009). 
 
Epidermal growth factor receptor (EGFR) normally controls various ​intracellular         
signal pathways in ​epithelial cells. The EGFR gene is often found upregulated and mutated in               
many cancers including gliomas. The most common mutation, EGFRvIII, is particularly           
associated with poor outcome for its ability to promote tumor growth, survival, invasion,             
metabolism and angiogenesis, and thus relates to many of the hallmarks of cancer. This              
biomarker is frequently screened for in an effort to tailor combination therapies as inefficient              
blood brain barrier penetration, intratumoral heterogeneity, compensatory signalling pathways         
and secondary mutations that all contribute to resistance (An et. al, 2018; Sigismund et. al,               
2018). 
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 Pertinent to the hallmark “enabling replicative immortality” is telomerase, an enzyme           
that adds protective repetitive DNA-sequences, telomeres, at the end of the chromosomes.            
Telomerase normally only remains active in the germ line and in activated stem cells and               
lymphocytes, and is suppressed during embryonic differentiation and are almost absent in            
normal cells. Every time a normal cell divides, the telomeres are shortened, and after about               
50-70 times cell-division stops in human cells. (Nugent et al., 1998; Zhou, 2014). Telomerase              
is active in many types of cancers however, thus enabling these cells to replicate almost               
indefinitely. Telomerase reverse transcriptase (TERT) is the catalytic subunit of telomerase           
that actually generates the sequences of cDNA that make up the telomeres (Sandin et. al,               
2014).  
 
Figure 2: ​Human telomere structure and telomerase recruitment. Telomeric DNA          
consists of arrays of the TTAGGG telomeric repeat, forming a long region of double stranded               
DNA terminating in the single stranded G-rich overhang. Telomerase is recruited to the tip of               
telomeres by the telomerase catalytic subunit TERT and through base pairing between the             
template region in the telomerase RNA subunit TER and the G-overhang. (From Sandin et. al,               
2014). 
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 Some mutations of TERT, particularly mutations C228T and C250T of its promoter            
region, cause a two to fourfold increase in transcriptional activity ​and, consequently, a             
positive regulation of telomerase activity in cancer cells. Mutations in the promoter (TERT)             
are strongly present in GBMs (83%), oligodendrogliomas (78%), oligoastrocytomas (25%),          
astrocytomas (10%) and in many other types of cancers. (Killela et. al, 2014; Mohammad et.               
al, 2016; Vinagre et. al, 2013). TERT promoter mutations are believed to be associated with               
aggressive behaviors and unfavorable outcomes in GBM, as well as overall survival (OS) and              
compromised progression free survival (PFS) in patients with gliomas. However, currently           
TERT promoter mutations are not qualified as a predictive biomarker. (Zhou, J. et al. 2014;               
Ohba, J. et al, 2016). Although this study focuses on the expression of TERT, not specifically                
on the mutations mentioned above, Masui et. al, 2018, found that both patients with and               
without a mutation of the TERT promoter had a higher expression of TERT protein measured               
with a TERT-specific antibody ​(TMab-6)​. 
 
1.4. Macroscopic and Histological Features  
GBMs are quite heterogeneous with pleomorphic cells composed of everything          
between small poorly differentiated tumor cells to large multinucleate cells. They present            
rapid growth, high glucose consumption, intra-tumor necrosis, hypoxia, abundant         
microvascular proliferation, hemorrhaging and, as is the focus of our study, blood-brain            
barrier destruction, perivascular infiltration of glioma cells and cerebral vasogenic edema.           
Studies indicate that tumor vessels are abnormal, and that the BBB that protects the brain's               
interstitial space from plasma leakage under normal conditions appear defective with exposed            
endothelial cell surface and irregular basal laminae. Consequently, it leads to junction            
opening, increased permeability, and edema formation. (Stummer, W., 2007). Another          
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 hypothesis proposes an increase in aquaporins (AQP) due to excessive growth factor            
stimulation which amplifies fluid leakage as well as tumor cell migration through the BBB.              
(Zador, et. al, 2016). 
 
1.5. Imaging 
Imaging can vary widely, but usually a central area of necrosis surrounded by white              
matter edema is present on an MR, and on a CT hypointense areas and a midline shift as a                   
result of moderate to severe edema can be seen (Nelson et. al. 2003). The size of the edema is                   
of prognostic value as studies have shown that the larger the edema the poorer outcome               
(Chen-Xing et. al, 2015). The size of the peritumoral edema is estimated as the maximum               
distance from the tumor margin to the outer edge of edema, as can be seen in the image below                   
from Chen-Xing’s article. 
 
Image 1: Determining size of peritumoral edema ​(A) Minor edema (<1 cm) shown by              
T2-W MRI. (B) Major edema (>1 cm) shown by T2-W MRI. (From Chen-Xing et. al, 2015). 
 
 
1.6. Treatment 
The primary treatment of GBM is surgical resection. However, the extent of how             
much of the tumor can be extracted is limited by the location and the functionality of the                 
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 afflicted area, and as such about 80% of the patients suffer relapse. Adjuvant treatment in the                
form of radiotherapy and chemotherapy is thus used in a majority of patients, and the               
European Association for Neuro-Oncology (EANO) have the following guidelines that          
considers the patients age, KPS and MGMT-methylation, as can be seen in the flowchart              
below in the figure from the article from Weller et. al, 2012. 
 
Figure 3: Clinical pathway for glioma ​Pathway for GBM highlighted. (From Weller et. al,              
2012). 
 
 
Serious side-effects such as radiation necrosis, radiation-induced permanent neuronal         
damage and even radio-resistance of some tumors has to be considered in the case of               
15 
 
 radiotherapy (Iacob and Dinca, 2009). Hypofractionated stereotactic radiotherapy have shown          
better results than hyperfractionated radiotherapy, and some novel therapies such as           
Intensity-modulated radiation therapy and boron neutron capture therapy have shown to be            
less toxic (Norden and Wen, 2006). In addition to radiotherapy, several chemotherapeutic            
agents have been tested, but Temozolomide (TMZ) which targets the tumor cells DNA             
mismatch repair system, blocks the cell cycle and triggers apoptosis, is the standard             
chemotherapy for patients with GBM (Reardon and Wen, 2006; Scott et. al. 2011). An              
analysis of the methylation of MGMT is used to determine which chemotherapeutic agent is              
to be used, and as mentioned above TMZ has been shown to work better on methylated                
MGMT (Stupp et. al, 2005, 2009; Malmstrom et. al, 2012; Wick et. al, 2012; Hansen et. al.                 
2018). Common side effects include gastrointestinal symptoms, nausea, headache, fatigue and           
hair loss, and the patient must be vigilant of signs of febrile neutropenia.  
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 2. JUSTIFICATION 
 
Currently, the therapeutic arsenal of GBM is surgical resection and adjuvant           
radiotherapy and chemotherapy. The survival length even with these very invasive treatments,            
however, is still short and ranges from 9 to 15 months. Furthermore, the effectiveness of these                
treatments varies depending on various clinical variables as well as biomarkers. For this end,              
identifying diagnostic and prognostic biomarkers is of importance to find a more specific and              
individually tailored treatment strategy for each patient. 
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 3. PURPOSE 
 
The purpose of this study is to correlate the level of TERT expression and the               
magnitude of cerebral edema in patients with GBM to their prognosis​, ​expressed as months of               
survival after the resection of the tumor which is the primary endpoint.  
 
In addition, survival will be correlated to other clinical variables, such as the patient's              
age, gender and location of the tumor. The study will also examine which of these clinical                
characteristics might be associated with TERT protein expression.  
 
In addition to these quantitative goals, several qualitative objectives for the           
professional development of the author were formulated and listed in Appendix A. As the              
results of these goals are not quantifiable but rather valuably add to the author's overall               
knowledge and experience, they will only be presented in Appendix A and not further              
scrutinized for specific results. 
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 4. MATERIAL AND METHODS 
 
4.1. Patients and samples 
Originally 28 patients with gliomas treated by the neurosurgery department of the            
private Hospital Santa Paula, São Paulo, Brazil, between 2010 and 2018 were selected             
regardless of age, gender and comorbidity. They were all patients of the advisor of the author,                
neurosurgeon and Professor Paulo Henrique Pires de Aguiar. A Karnofsky’s Performance           
Status (KPS) was estimated for each patient to evaluate their overall wellbeing and how well               
they would tolerate adjuvant treatment. The patients then underwent radical resection of the             
tumor where a sample was collected, and thereafter received adjuvant chemotherapy           
(temozolomide) and radiotherapy, and a histological analysis was performed. It was later            
decided in accordance with the Swedish advisor that only patients with a diagnosis of GBM               
should be selected since the primary endpoint, overall survival, differs vastly between the             
various grades of gliomas. This meant that only the 12 patients with GBM were selected. 
 
4.2 Ethical considerations 
The project was evaluated by the Research Ethics Committee of the Santa Paula             
Hospital, submitted on May 29, 2018, and approved (approval id CAAE           
91035018.5.0000.5670), being appropriate and meeting the requirements of resolutions         
196/96 and 466/12. Clinical data of patients enrolled in the study were collected from medical               
records. All patients received the same treatment as they would outside the study, and the               
brain samples that were analysed were part of the resections that needed to be removed. A                
written letter of agreement was signed by each patient.  
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 4.3. Study period 
The study began in August 2018 and ended in December 2019.  
 
4.4. Eligibility Criteria 
Patients diagnosed with GBM between 2010 and 2018 from the private Hospital Santa             
Paula, regardless of gender, age and comorbidity. The characterization of the type of tumor              
and its grade was done by a histopathological analysis according to the classification of the               
World Health Organization (WHO). Only Glioblastomas were accepted. 
 
4.5.  Data and sample collection 
All patients underwent surgery and a tumor tissue sample was obtained. Data was             
collected from the medical records and from the MRIs of patients treated by the neurosurgery               
department of Hospital Santa Paula in August 2018.  
 
4.6. Histopathological evaluation 
This was performed by the pathology department in Hospital Santa Paula. The            
extracted samples were fixated in a formaldehyde 10% for 24 hours. They were then washed               
in running water and put in a decalcification solution. Afterwards they were embedded in              
paraffin wax and cut longitudinally in 4µm thick slices. Two slices were mounted on glass               
slides according to the Hematoxylin and Eosin (HE) staining technique for the histological             
analysis This stains unspecifically the nuclei of the cells blue and other tissue pink.  
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 Image 2: Demonstration of a hematoxylin and Eosin (HE) staining from nonspecific            
tissue​.  
 
 
Through microscopic inspection of the slides the presence of tumor, inflammatory           
infiltration, necrosis and mitotic activity was estimated and the degree of malignity of the              
tumor could be determined according to the WHO ​classification of 2007 which includes a              
grading scheme that is a malignancy scale ranging across a wide variety of neoplasms rather               
than a strict histological grading system. (Louis et. al, 2007). The exact procedure and further               
description of the results is not available. 
 
4.7. Immunohistochemical technique of the protein expression 
Immunohistochemistry (IHC) was done at the laboratory of Clinical Analysis at           
FMABC. The general principle is depicted in the image below. 
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 Figure 4: General principle of IHC. 
 
 
Additional slices of the samples embedded in paraffin wax were cut with the same              
width, 4µm, and underwent immunohistochemistry with a specific primary antibody for           
TERTs, TERT (A-6) mouse monoclonal IgG2b (4 publications reference this antibody, no            
cited validations) from Santa Cruz Biotechnology, Inc (Figure 4, step 1). The paraffine from              
the slices was removed by placing them in a bath containing Trilogy IHC Pre-treatment              
Solution (Sigma-Aldrich Corporation®, Saint Louis, USA) for 40 minutes at 95ºC. The slices             
were then placed in three consecutive baths of 5 minutes each in a solution of sodium                
phosphate buffer (PBS), 0.05M with a pH of 7.2. The endogenous peroxidases were blocked              
with a 3% hydrogen peroxide 30 Vol. solution in a tank at room temperature for 40 minutes,                 
then followed by three 5 minutes baths in PBS. Peroxide 30 Vol. means that 1 L of solution                  
produces 30 L of O₂ via the reaction 2 H₂O₂ → 2 H₂O + O₂. ​Next, incubation with the                   
primary antibody was performed using the primary antibody diluted to the ratio recommended             
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 by the manufacturer, 1% PBS/BSA solution (Sigma-Aldrich Corporation, Saint Louis, USA).           
All sections were covered with about 100µL of solution and kept in a humid chamber at room                 
temperature for 2 hours. The slices were washed in 3 successive PBS baths for 5 minutes                
each. The sections were then incubated in a humid chamber at room temperature with a               
secondary antibody, m-IgGκ (247 publications reference this antibody, no cited validations)           
from Santa Cruz Biotechnology with biotin-streptavidin complex (Dako Denmark A / S®,            
Glostrup, DK) in the following procedure: incubation with biotin for 40 minutes; 3 successive              
PBS washes for 5 minutes each; and finally incubation with streptavidin for 40 minutes              
(Figure 4, step 2 and 3). After yet another 3 baths in PBS, the slides were developed using                  
diaminobenzidine chromogen which should produce a brown color as a positive signal (DAB             
Enhancer, Dako Denmark A / S®, Glostrup, DK) (Figure 4, step 4). This solution was               
prepared five minutes before the end of the exposure time of the slides, pipetted over the                
samples and covered them for 20 minutes. The slides were then washed in 3 successive PBS                
baths for 5 minutes each. Counterstaining was done with Harris Hematoxylin (Sigma-Aldrich            
Corporation®, Saint Louis, USA) in a tank for 30 seconds. Hematoxylin is ‘blued’ with a               
weakly alkaline solution. The final dehydration process of the slides was as follows: distilled              
water (5 minutes), 70% ethanol (5 minutes), 80% ethanol (5 minutes), 90% ethanol (5              
minutes), 100% ethanol (5 minutes) ), 100% ethanol 2 (5 minutes), xylol 1 (5 minutes) and                
xylol 1 (5 minutes). Finally, slides were mounted with coverslip and Permount (Fisher             
Scientific, Pittsburgh, USA).  
 
4.8. Determining protein expression in neoplastic tissue 
This step was performed at the FMABC Clinical Analysis Laboratory. Microscopic           
analysis of the slides was performed with the aid of a common optical microscope, with the                
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 aid of a 40X objective lens and a final magnification of 400X. The immunohistochemical              
analysis of protein expression consists of 5 photographs of different parts of each slide, one               
slide from each patient. With the help of three observers, including the advisor dr Paulo, the                
classification of the protein expression intensity in the slides. Each observer gave subjectively             
one or two crosses to each sample to classify them as low or high in expression. The reaction                  
was considered positive where there was a higher intensity of purple staining the nuclei along               
with discreet staining of brown which signals that the DAB-chromogen (brown) has attached             
via the secondary and primary antibodies to the TERT-antigen, and when the expression             
occurred diffusely, with points of varying intensities and homogeneous distribution. Since           
there was no way to beforehand determine a tissue sample that undoubtedly expressed the              
TERT protein and could serve as a positive control, TERT (h): 293T Lysate (Santa Cruz               
Biotechnology, Inc) was used as a positive control to validate the primary antibody. No record               
of the exact procedure is available, neither is any record of a positive control of the secondary                 
antibody. The slides were also compared to the negative control, collected from the temporal              
lobe during a lobectomy of an epilepsy patient (see image 3 below). The histopathological              
analysis also concluded the sample as void of glioma and thus was assumed to have no or                 
very little expression of TERT which previous studies have shown is the case in normal               
central nervous tissue (Liu et. al, 2018). The observers were not blinded to each other.  
 
4.9. Classification of peritumoral edema 
The size of the peritumoral edemas were estimated according to Schoenegger et. al.             
(2009) from the MRI-scans, and classified as minor (<1 cm) and major (>1 cm) from               
T2-weighted images, as is illustrated in image 1. This was performed by the Brazilian advisor               
at Hospital Santa Paula.  
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4.10. Statistical analysis of the results 
Initially the project analysed the samples of all of the 28 patients, even the ones with                
lower grade gliomas. It was later decided in accordance with the Swedish advisor, professor              
and neurosurgeon Bertil Rydenhag, to narrow the study to only permit glioblastomas, which             
meant that only 12 patients were ultimately included in the study. This however gave the               
study too little power for a multivariable analysis. Hence, due to the low number of samples                
only a descriptive analysis was performed.  
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 5. RESULTS 
 
The 12 samples of tissue with glioblastoma were classified according to age (in years at               
the moment of surgery), gender, type and grade (according to WHO), and the location of the                
tumor. The peritumoral edema was also classified as either minor or major. The length of               
survival during the study-period expressed in months after surgery was last updated in             
December 2019. At the end of the study-period in December 2019, the minimum time that               
had passed since surgery for all patients was 20 months, thus this was chosen as the censoring                 
period. Finally, KPS was estimated for the patients, a scale that measures the patient's overall               
wellbeing where 100 is healthy and 0 is dead. This is summarized in the table below. 
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 Table 3: Clinical characteristics of the patients with glioblastoma  
Patient Age Sex Type/ 
Grade 
Location Edema Survival KPS 
1.  84 Male ASTRO 
IV 
Right angular gyrus and 
supramarginal gyrus (parietal 
lobe) 
Major 2 - 
2.  66 Male ASTRO 
IV 
Left middle and inferior temporal 
gyrus 
Minor >20 100 
3.  56 Male ASTRO 
IV 
Left precentral gyrus (frontal 
lobe) 
Minor >20 80 
4.  56 Male ASTRO 
IV 
Left angular gyrus and 
supramarginal gyrus (parietal 
lobe) 
Major 4 - 
8.  66 Male ASTRO 
IV 
Left temporal lobe Major >20 100 
9.  66 Male ASTRO 
IV 
Left angular gyrus and 
supramarginal gyrus (parietal 
lobe) 
Major 15 - 
13.  54 Male ASTRO 
IV 
Right frontal lobe Major 10 - 
14.  52 Female ASTRO 
IV 
Basal ganglia and the left medial 
temporal lobe 
Major >20 60 
16.  58 Male ASTRO 
IV 
Basal ganglia and the left medial 
temporal lobe 
Minor 13 - 
20. 58 Female ASTRO 
IV 
Left frontal lobe Major >20 70 
24.  71 Male ASTRO 
IV 
Left temporal lobe Major >20 80 
28.  48 Female ASTRO 
IV 
Left frontal lobe Major >20 100 
 
The average age at the date of surgical resection was 61.2 years. Out of the 12 patients,                 
9 were male and only 3 were female. The location of the tumors was distributed as follows: 4                  
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 were located in the frontal lobe, 3 were located in the parietal lobe, and 5 were located in the                   
temporal lobe. The peritumoral edemas were predominantly large: 9 were classified as major             
and 3 as minor. Five of the twelve patients passed away during the study and within the 20                  
months censoring period. The rest of the patients were followed until December 2019. KPS              
was only done for 7 of the 12 patients and ranged between 60 and 100. (Table 4). 
Table 4: Clinical variables from all 12 patients 
Variables Patients 
Average age 61.2 years. 
 
Sex 9 (75%) men. 
3 (25%) women. 
Tumor location 4 (33.3%) frontal lobe. 
3 (25%) parietal lobe. 
5 (41.7%) temporal lobe. 
Peritumoral Edema 9 (75%) major. 
3 (25%) minor. 
Deceased 5 (41.7%) deceased within 20 months after resection. 
 
KPS Between 60 and 100. 
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 5.1. Results from TERT protein analysis 
The immunohistochemical analysis of the protein expression was performed with the           
negative control as reference. No further reference to the positive control is found. 
 
Image 3: Negative control of the reaction 
 
 
Some of the samples (1 and 9) could not be processed and are marked as “(error)” in                  
table 5. Among the 10 samples that could be analysed, 4 showed an elevated protein               
expression of TERT, as can be compared to the reference and observed in the delimited areas                
in the images below as a deeper purple color staining the nucleus along with staining of                
brown which signals that the DAB-chromogen (brown) has attached via the secondary and             
primary antibodies to the TERT-antigen, and is summarized in table 5. 
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 Image 4, 5, 6, 7: Samples of tumors from patients in the study. ​The areas with a stronger                  
purple from the nucleus with brown around delimited in the images below are supposed to               
show a higher intensity of reaction characterizing an elevated protein expression of TERT. 
  
4 5 
  
6 7 
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 Table 5: Table 2 updated with protein expression of TERT. 
Patient Age Sex Type/ 
Grade 
Location Edema Survival 
months 
Protein 
Expression 
1.  84 Male ASTRO 
IV 
Right angular gyrus 
and supramarginal 
gyrus (parietal lobe) 
Major 2 (error) 
2.  66 Male ASTRO 
IV 
Left middle and 
inferior temporal gyrus 
Minor >20 High 
3.  56 Male ASTRO 
IV 
Left precentral gyrus 
(frontal lobe) 
Minor >20 High 
4.  56 Male ASTRO 
IV 
Left angular gyrus and 
supramarginal gyrus 
(parietal lobe) 
Major 4 Low 
8.  66 Male ASTRO 
IV 
Left temporal lobe Major >20 Low 
9.  66 Male ASTRO 
IV 
Left angular gyrus and 
supramarginal gyrus 
(parietal lobe) 
Major 15 (error) 
13.  54 Male ASTRO 
IV 
Right frontal lobe Major 10 Low 
14.  52 Female ASTRO 
IV 
Basal ganglia and the 
left medial temporal 
lobe 
Major >20 High 
16.  58 Male ASTRO 
IV 
Basal ganglia and the 
left medial temporal 
lobe 
Minor 13 Low 
20. 58 Female ASTRO 
IV 
Left frontal lobe Major >20 Low 
24.  71 Male ASTRO 
IV 
Left temporal lobe Major >20 Low 
28.  48 Female ASTRO 
IV 
Left frontal lobe Major >20 High 
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 5.2. Results in patients with high TERT protein expression 
The 4 patients that had a high positive expression of TERT protein was 55.5 years as                
compared to the average age of 61.2 years for the whole group. The gender distribution was                
equal with 2 women and 2 men. However, women showed a higher proportion of TERT               
expression than men (66.7% vs 22.2%). ​Half of the TERT-positive tumors were located in the               
frontal lobe, half in the temporal lobe, and none in the parietal lobe. Major and minor                
peritumoral edemas were equally common in TERT-positive tumors. However, the          
percentage of tumors with minor edemas that expressed TERT was higher (2 out of 3               
samples, 66.7%) than for the tumors with major edemas (2 out of 9 samples, 22.2%). It should                 
be noted that 2 of the samples from the tumors with major edemas were corrupted, so this last                  
number could actually be higher (2-4 out of 9 samples, 22.2-44.4%). None of the four               
TERT-positive patients passed away during the study. However, 2 of the 5 deceased patients              
had their samples corrupted and could not be analysed for the presence of TERT (table               
below). 
 
 
32 
 
 Table 6: Patients with high protein expression of TERT. 
Variables Patients with positive protein expression of TERT (4 
patients) 
Average age 55.5 (vs 61.2*) years. 
 
Sex 2 (50% vs 75%) men.  
 
2 (50% vs 25%) women.  
 
Tumor location 2 (50% vs 33.3%) frontal lobe (of 4 GBMs located here). 
0 (0% vs 25%) parietal lobe (of 3 GBMs located here). 
2 (50% vs 41.7%) temporal lobe (of 5 GBMs located here). 
Peritumoral Edema 2 (50% vs 75%) major. 
 
2 (50% vs 25%) minor.  
 
Deceased 0 (vs 5). 
 
* Compared to the whole group of 12 patients. 
 
5.3. Results in patients with poor outcome 
The average age for the 5 patients that died during the 20 months censoring period was                
63.6 years as compared to the average age of 61.2 years for the whole group. These patients                 
survived on an average for 8.8 months. The deceased were all men. ​The majority of the                
tumors in the deceased patients were located in the parietal lobe. In fact, all the patients                
diagnosed with GBM in the parietal lobe died, compared to 25% of the patients with tumors                
in the frontal lobe and 20% in the temporal lobe. The majority of the tumors (80%) had a                  
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 major peritumoral edema. This is almost the same proportion as for the entire group of               
patients (75%). None of the deceased patients expressed the TERT protein. Note however that              
the tissue samples from 2 of the deceased could not analysed as described above, and it is                 
possible that they were positive. 
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 6. DISCUSSION 
 
This study contained a limited number of patients and no statistical significance can be              
given to any of its relationships. Hopefully however, this study and the conclusions drawn              
from it can be hypothesis generating and give hints to future research and how it should be                 
improved.  
 
In this study we concluded that in the patients with positive protein expression of              
TERT in GBMs, there seems to be a slight negative relationship between advanced age and               
intensity of protein expression. Among the patients that showed a positive protein expression             
of TERT, the average age was 55.5 years, compared to the average age for the whole group of                  
61.2 years. This could suggest that there is a higher degree of protein expression of TERT in                 
younger patients. Also, although women are less likely to be afflicted by GBMs, they had a                
higher tendency to express the protein in our study. The protein expression of TERT was               
positive in 66.7% of the women and only 22.2 % of the men. However, the average age for                  
these women were 50 years, whereas for the men 61 years, and as indicated above TERT                
seems to be expressed more in younger patients which might explain this difference. In future               
research a larger sample could help deduce if the actual relationship between these three              
factors. Also, a more careful and standardized collection of the samples is necessary as two of                
the samples could not be processed due to an insufficient amount of tissue. 
 
As for any relationship between the location of the GBM and protein expression, no              
obvious pattern could be discerned. As for the size of the peritumoral edema, where there was                
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 a smaller edema the expression of TERT was more frequently present than if the edema was                
large.  
 
During the study, 5 of the 12 patients died within 20 the months censoring period, and                
on average 8.8 months after surgery. All of them were men, and they were on average 2.4                 
years older than the whole study group as is expected from previous studies (Fekete et. al.                
2016).  
 
None of the deceased patients expressed TERT, which is contrary to our initial              
assumption that a higher TERT-expression is related to a poorer prognosis as is the case with                
some mutated versions of TERT. This could perhaps be explained by the fact that the               
expression of TERT-protein seems to be higher in younger people, and old age has been               
shown to be correlated to poorer outcome (Stark et. al. 2012). This study also did not                
differentiate between mutated and unmutated TERT, neither did it analyse the existence of the              
mutated versions (C228T and C250T) which can co-exist and indeed tend to be associated              
with an upregulated level of unmutated TERT (Mausi et. al. 2018). It would have been of                
interest to see if any of the TERT-positive samples also sported any of these mutations despite                
the fact that none of these patients died. In addition to the mutated versions of TERT, the                 
presence of mutated IDH is of particular interest as it is a recognized prognostic factor and                
proven to be associated with better outcome. Studies have shown that TERT promoter             
mutation is associated with reduced overall survival in IDH-mutant glioblastomas (Vuong et.            
al. 2017), and it would be interesting in future studies to see if there is a similar relationship                  
with unmutated TERT. 
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 All but one of the deceased had major peritumoral edema. As for the location of the                
tumors in the deceased patients, the majority were located in the parietal lobe. In fact, all of                 
the patients with tumors in the parietal lobe died, as compared to 25 of the patients with                 
GBMs in the frontal lobe, and 20% in the temporal lobe. This might suggest that GBMs                
located in the parietal lobe are associated with worse prognosis, perhaps due to symptoms              
from particularly a non-dominant parietal lobe being less obvious and more easily confused             
with dementia and thus leading to later diagnosis. An early study has also indicated that               
resections of tumors in the frontal lobe might be associated with a longer survival (Jeremic et.                
al. 1994), and overall tumors located supratentorially and in cerebellum are more easily             
accessed and removed than those located in the diencephalon or brainstem (Walid, 2008;             
Awad et. al, 2017). 
 
Another weakness of the study that should be addressed in future studies is the method               
of visual analysis of the immunohistological samples, where using an image processing            
technique could assist in more accurately determine the level of protein expression. It was              
difficult for the untrained eye to identify the areas with more areas of deep purple staining the                 
nuclei and brown around cells supposedly denoting accentuated TERT-protein activity. It was            
also difficult for the naked eye to determine what would be considered a high vs a low level                  
of TERT-protein expression. This could be much improved by using imaging processing            
techniques. In addition, there was only one slide per patient, and since GBMs usually exhibit               
molecular heterogeneity this might have limited the ability to correctly identify areas with             
TERT protein expression (Parker et. al, 2015).  
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 A lot can go wrong when analysing immunohistochemically, and the interpretation is            
subject to each pathologist’s interpretation which studies have shown is seldom replicable            
(Giannini et. al, 2001). This is one of the main reasons genetic biomarkers have become more                
important in classifying gliomas, choose therapy strategies, and predict outcome (Szopa et. al,             
2016). The actual immunohistochemical process is also prone to error if not performed             
perfectly, and sometimes even the datasheet with instructions that accompanies the antibodies            
cannot be followed blindly and preliminary tests have to be done for instance to determine the                
perfect concentration of the antibody. Distinguishing the positive results against the           
background is another problem. Monoclonal antibodies, which was chosen for this study,            
causes less noise as it binds more specifically to the agent, and is more easily distinguished                
against the background. Normally DAB-staining is colored brown which gives a quite clear             
contrast to the Hematoxylin-Eosin-staining, but by binding Streptavidin to the biotin attached            
to the secondary antibody, other colors (or chromogens), even fluorescent, can be chosen that              
better differentiate the positive results from the background. In this study it clearly states that               
DAB is used, but the positive signal is difficult to see. According to the Brazilian advisor,                
sometimes the the purple from the stained nuclei can almost drown out the brown from the                
DAB when the staining is not performed exactly as instructed and the            
Hematoxylin-Eosin-staining end up being too strong and the DAB-staining too weak. In this             
case it indeed seems there is a high background. It is also possible that the results are not                  
positive at all, and the fact that the positive control that the study points to is no longer                  
available makes this impossible to assess retrospectively. 
 
Also, a problem with using biotin is that it is expressed endogenously in many cells                
raising the question of potential false-positive results. This is most common in the liver,              
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 kidney and spleen, but neurons associated with the cerebellar motor system and the brainstem              
auditory system have also shown to express significant levels of biotin (McKay et. al, 2008).               
Other possible reasons for false positive results are improper handling of tissue that has left it                
too dry, or because the staining or incubation of the antibody lasts too long. Another of many                 
pitfalls with IHC is that there are no universally accepted guidelines or standardized methods              
for determining their validity of the antibodies. The antibodies should be specific, selective,             
and the studies for which they are used should be reproducible. Information about validation              
is often lacking from the manufacturer as is also the case in this study, but the number of                  
publications the antibody is cited in can serve as an indirect indicator of its validity (Bordeaux                
et. al, 2010). Another weakness of this study is the uncertainty of the primary antibody, TERT                
(A-6) mouse antibody IgG2b, that has only been cited in 4 publications and has no available                
information about validation. The secondary antibody however, m-IgGκ BP-HRP, has been           
cited in 247 publications giving it more credibility despite no available information about             
validations. Positive and negative controls of the antibodies are often not reported in             
publications which may lead to incorrect interpretations and irreproducible results (Hewitt et.            
al, 2014). There is a mention of the positive control being used for the primary antibody in                 
this study, but the exact protocol followed is not detailed which brings into question the               
validity of it. Also, there is no mention of a positive control of the secondary antibody. As for                  
the negative control, it comes from a sample that is histopathologically assumed to be devoid               
of cancerous cells, but as has been discussed above, histopathological evaluations are subject             
to the often unreproducible evaluation of the pathologist which brings into question if it is               
really a negative control. 
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 Also, a more detailed inclusion criteria where relevant comorbidity is considered, as            
well as a more complete record of KPS, could benefit the conclusions of future studies as they                 
are important factors for overall survival, selection of treatment and the identification of             
high-risk patients. It is of course important to know what actually caused the death of a                
patient, the glioblastoma or an unrelated condition, to avoid any false conclusions from the              
data. Furthermore, all patients received adjuvant radio- and chemotherapy, but detailed           
individual information about dosage of chemotherapy, grays administered during radiotherapy          
and specific method used, etc, was outside the scope of this study but could be of interest for                  
future study. There are specific guidelines to what exact treatment should be chosen             
depending on the type of glioma, mutations, KPS and age of the patient, but there is no                 
mention of such a protocol being followed in the data (Weller et. al, 2017). Neither was there                 
information in the data about MGMT-status, which is an important factor for determining the              
selection of treatment and expected outcome. 
 
Yet another great weakness was the lack of detail in the data about the selection               
criteria of the patients. A fairly limited number of patients (initially 28) were selected in a                
rather large period of time (8 years). All patients also belonged to one single private hospital                
which is unavailable for all but a few in a high socioeconomic group, which could mean that                 
the results found in this study are not transferable to a normal population due to selection bias.  
 
Perhaps the biggest weakness was that the focus of the research radically changed             
twice during the process. The initial project was intended to focus on the relationship between               
TERT promoter mutation and peritumoral edema, which was the focus of the authors             
bibliographical survey. When further analysing the data handed to the author, however, it             
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 became clear that the samples had been analysed for the presence of overall TERT expression,               
rather than for the mutated kind. The samples also contained a large selection of patients with                
other types of gliomas. A paper was then written based on these findings, excluding the               
bibliographic survey. Finally, it was decided that since the primary objective was overall             
survival and patients with the various grades of gliomas have very different expected survival,              
the paper needed to focus solely on GBMs. These repeated changes jeopardised the integrity              
of the study. Since the mutations play a vital role in augmenting the expression of TERT, it                 
would have been interesting to differentiate between mutated and unmutated expression of            
TERT using PCR as IHC at least in other types of cancer has been shown to be a poor method                    
for determining the expression of TERT mutations (Paulson et. al, 2018). The study did              
initially try to perform a genetic analysis using PCR to determine genetic expression of TERT               
but the process only showed a positive result in one of the subjects, leading to the conclusion                 
that the PCR had somehow been performed erroneously or the samples had been corrupted.              
The lack of results of the PCR lead the examinator to recommend it was removed from the                 
project and it is therefore no longer present in the current version. 
 
A strength could however be found in the fact that all the patients were treated by the                 
same surgeon, thus minimizing the variability in quality of treatment due to differences in the               
skills of the surgeons. Another strength was the length that the patients were followed, a               
minimum of 20 months which is well beyond the estimated length of survival for the vast                
majority of patients with GBM. 
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 APPENDIX A 
 
ACTIVITIES DURING STUDY-PERIOD CONTRIBUTING TO THE      
PROFESSIONAL DEVELOPMENT OF THE AUTHOR 
 
Of the full study period the author spent 3 months in Brazil analysing the data from                
the study and working on this paper, as well as engaging in many activities pertinent to the                 
qualitative objectives detailed below. 
 
 
1. Qualitative objectives of study 
  
To gain clinical experience from assisting experienced neurologists and neurosurgeons          
in assessing a great number of patients with wide variety of neurological conditions, and              
specifically pertinent to this study, identify patients with brain tumors.  
 
To learn about the neurosurgical procedures from some of the most experienced            
neurosurgeons in Brazil and assist in a large number of different types of brain surgeries. Of                
specific interest for the project was oncological brain surgery. 
  
To increase theoretical knowledge in the fields of neurology, neurosurgery and           
neuro-oncology.  
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 To expand my knowledge in different methods of research, and if possible, to get              
involved in other research projects related to neurology and neurosurgery.  
 
Networking, to get to know as many people as possible in the field of neurology and                
neurosurgery in Brazil as possible. 
 
 
2. Activities relevant to the qualitative objectives 
 
Mondays and fridays I would spend in an office located in the University Pontificia              
Universidade Catolica and the adjacent Hospital Santa Lucinda in Sorocaba, Brazil, where the             
advisor, neurosurgeon and professor Paulo Henrique de Pires Aguiar, also held lectures for             
the interns in neurology and neurosurgery. Here I would summarize and analyse the data from               
the patients in the study, do further research in PubMed, read from the book “Principios               
Tecnicos de Neurocirurgia, Atlas e texto” written by the advisor, watch a vast library of               
videos of surgical procedures done by the advisor, and write on the thesis. In addition, I was                 
allowed to attend many of the lectures in neurology and neurosurgery, for instance             
“Neurosurgical treatment of pain” and “Neurotrauma - clinical applications”. I shared an            
office with a research assistant, biologist and neuropsychologist, Lucia Canaberra, that           
coordinated many of research projects at the university, and who also set up the various               
experiments done on cadavers or laboratory rats in the adjacent rooms. Lucia went to great               
lengths to teach me about the various techniques that they used in their research, and to                
present and even include me in various research projects. Particularly memorable was a study              
about vasospasm (a condition utterly important for anybody dealing with neurosurgery) where            
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 I was taught the use of stereotaxy to induce subarachnoid haemorrhage in a mouse brain and                
then measure the level of vasospasm using a transcranial doppler. Another clinical research             
project involved measuring various structures of the brain using precision tools on cadaver’s             
brains, which was a very educative addition to my previous anatomy studies. All these              
experiments had some connection to this project, for instance by increasing the knowledge of              
anatomy and pathophysiology, to learn how to identify and deal with differential diagnosis,             
and to be able to handle various neurological complications. It also allowed me ample              
opportunities to network and to get to know very well the various departments at the               
university and the adjacent hospital with its staff. There was also a 3-day course in endoscopic                
surgery arranged by Johnson & Johnson and Dr Burgesi, a surgeon at Hospital Santa Lucinda,               
that I attended.  
 
Tuesdays, Thursdays and Saturday mornings I spent in surgery in various hospitals in             
São Paulo, particularly Hospital Santa Paula and Hospital Sírio-Libanês. The patients mainly            
had tumors of various types, but other conditions such as for instance aneurysms, herniated              
discs and spinal stenosis were also treated. Most of these surgeries were performed by the               
advisor dr Paulo, dr Marcos Perocco or dr Marcos Vinicius. When circumstances would not              
allow surgery on one of these days in Sao Paulo, I would be invited to other types of surgery                   
in the Hospital Santa Lucinda in Sorocaba. This would often involve craniofacial plastic             
surgery with dr Décio Portello. 
 
A couple of Wednesdays I was privileged to spend at dr Paulos doctor’s clinic in São                
Paulo, adjacent to both Hospital Sírio-Libanês and Hospital Santa Paula, where he and dr              
Marcos Perocco attended patients with all types of neurological afflictions. This allowed me             
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 invaluable knowledge in taking anamneses, physical status and differentiating between          
neurological conditions, and especially identify clinical signs of patients with tumors. On a             
normal day each doctor would attend 15 patients or more. To illustrate the variety of patients,                
the diagnosis from my notes of one single day are listed as follows: hemangioma due to ​von                 
Hippel-Lindau syndrome​; rhizotomy for nerve pain from cervical arthrosis; neuropathic pain           
after medullary infarction; implantation of occipital nerve stimulation; occipital trauma;          
cavernoma; cholesteatoma and surgery of n. facialis; nerve grafting of n. axillaris; paraplegic             
after motorbike injury; subdural hematoma; aneurysm clip; stroke cerebellum; lumbago;          
headache after trauma; lumbar spinal fusion; spinal stenos; brain metastasis of type            
adenocarcinoma originating from the colon; herniated lumbar disc. On some occasions I was             
allowed to partake in conferences between neurosurgeons at Hospital Sírio-Libanês that was            
just across the street, and listen to them giving lectures about different patients of particular               
educational interest, for instance lectures “Neuro-oncology, meningiomas and intraventricular         
tumors”, and “Correlation between neuroanatomy and radiology”. 
 
I also spent some of these days in FMABC in Sao Paulo observing the various               
research techniques described below under guidance of the advisor dr Paulo and his pupil,              
Anne Martinez. Because of security reasons I was not allowed there alone and could only go                
there on a couple occasions with the advisor and his bodyguard in his armoured car. The                
security-issues limited considerably my ability to move around, and I myself unfortunately            
became a neurology patient for a short time at the Hospital Sírio-Libanês after being assaulted               
and suffering head-trauma, which accounted for a period of 2 weeks of limited academic              
activity. At FMABC I made several contacts, in particular professor in neurology Marco Pristi              
and professor in statistics Luiz Carlos de Abreu. 
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In addition to these and other activities organized by the very enthusiastic and             
welcoming advisor dr Paulo was a 3-day neurosurgical conference in Curitiba, Brazil, in the              
beginning of November 2019. This involved ample opportunity for networking and a full             
schedule of lectures, most notably “Epilepsy surgery” by the advisor dr Paulo, “Endoscopic             
endonasal surgery of pituitary adenomas” by dr Apio Claudio Martins Antunes, and            
“Intracranial hypertension” by dr Carlos Tadeu Parisi de Oliveira, all of whom I had the               
opportunity to meet and converse further on these and other topics related to neurosurgery. 
 
As for the selection of patients and samples, originally 28 patients with gliomas were              
selected and I wrote a paper that focused on all these patients. It was later decided in                 
accordance with the Swedish advisor, professor and neurosurgeon Bertil Rydenhag, that only            
the 12 patients with a diagnosis of GBM should be selected so I rewrote the original paper.                 
All patients underwent surgery and a tumor tissue sample was obtained prior to my arrival in                
Brazil. In later sessions of surgery of other neuro-oncological patients I observed several             
surgeries of gliomas and the collection of samples. 
 
As for the data and sample collection, this was collected by the advisor upon one of                
the various stays at the hospital and handed to me for analysis as I was not granted direct                  
access to the medical records due to hospital policy.  
 
As for the histopathological evaluation, this was performed by the pathology           
department in Hospital Santa Paula prior to my arrival in Brazil. I was not able to assist in this                   
procedure for future patients that I had later assisted surgery for due to the policy of the                 
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 private Hospital Santa Paula, and the procedure had to be detailed by the advisor.  
 
As for the immunohistochemical technique of the protein expression, this was done at             
the laboratory of Clinical Analysis at FMABC prior to my arrival. Upon arrival, I was shown                
the procedure on other samples at FMABC by the advisor and staff.  
 
As for determining protein expression in neoplastic tissue, this step was performed at             
the FMABC Clinical Analysis Laboratory. This had been done prior to my arrival. Upon              
arrival the photos of each sample were handed over to me in a session where one of the                  
advisor’s pupils, Anne Martinez, explained the results. 
 
As for the classification of peritumoral edema, this was performed by the Brazilian             
advisor before I arrived in Brazil. The results were passed on to me, and the methodology was                 
described during a session with the advisor at Hospital Santa Paula where I could observe a                
selection of MRI-images.  
 
As for the statistical analysis of the results, initially the project analysed the samples of               
all of the 28 patients, even the ones with lower grade gliomas, and a multivariable analysis                
relating poor outcome to the two independent factors TERT-expression and size of the             
peritumoral edema was performed by me. The sample was then 28 patients which allowed              
sufficient power for two independent factors. I wrote a thesis based on these results, but it was                 
later decided in accordance with the Swedish advisor to narrow the study to only permit               
glioblastomas, which meant that only 12 patients were ultimately included in the study. This              
however gave the study too little power for a multivariable analysis. Hence, due to the low                
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 number of samples only a descriptive analysis was performed.  
 
The study did initially try to perform a genetic analysis using PCR to determine              
genetic expression of TERT but the process only showed a positive result in one of the                
subjects, leading to the conclusion that the PCR had somehow been performed erroneously or              
the samples had been corrupted. The lack of results of the PCR lead the examinator to                
recommend it was removed from the project and it is therefore no longer present in the                
current version. This was done prior to my arrival in Brazil and was later summarized to me                 
by the advisor.  
 
The author also spent august and September 2019 doing a bibliographical survey in             
Gothenburg, Sweden, detailed in Appendix B. 
56 
 
 APPENDIX B 
 
BIBLIOGRAPHIC SURVEY  
 
In the bibliographic survey that was done in the online database PubMed, articles that              
showed any relationship between TERT promoter mutations and/or peritumoral swelling as           
possible prognostic factors in patients with GBMs were chosen. Only articles published            
between 2008 and 2019 in English were considered, with a minimum number of subjects in               
the study being 100, and an impact factor 1.0 or above. As the study subsequently ended up                 
not differentiating between mutated and unmutated TERT, the bibliographical survey was           
added as an Appendix rather than integrated into the study itself. 
 
Table 1: Bibliographic survey  
Article / Author Year Conclusion 
TERT ​promoter  
mutations and  
polymorphisms as  
prognostic factors in   
primary glioblastoma  
Mohamed Ali  
Mosrati 
2015 Mutation of the TERT promoter was associated with a         
lower length of survival (11 vs. 20 months and 12 vs.           
20 months for the mutation C228T and C250T,        
respectively). 
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 Combined analysis  
of ​TERT ​, ​EGFR​, and    
IDH ​status defines   
distinct prognostic  
glioblastoma classes 
Marianne Labussière 
2014 The mutation of the TERT promoter was associated        
with a bad prognosis, with an average survival of 13,8          
vs 37,6 months, when IDH also was mutated. When         
IDH was not mutated the difference was 13,7 vs 17,5          
months.  
TERT ​promoter  
mutations in primary   
and secondary  
glioblastomas  
Naosuke Nonoguchi 
2013 TERT mutations had no significant impact on patients'        
survival in multivariate analysis after further adjusting       
for other genetic alterations, or when primary and        
secondary glioblastomas were separately analysed.     
These results suggest that the prognostic value of        
TERT mutations for poor survival is largely due to         
their inverse correlation with IDH1 mutations, which       
are a significant prognostic marker of better survival in         
patients with secondary glioblastomas. 
 
Prognostic quality of   
activating TERT  
promoter mutations 
in glioblastoma:  
interaction with the   
rs2853669 
2015 Seventy-three percent of GBM patients harbored      
TERT promoter mutations. Patients with mutated      
tumors exhibited significantly shorter overall survival      
in the entire cohort (11.5 vs 23.1 months) and in the           
primary GBM patient subgroup lacking IDH1      
mutations. This prognostic impact was confined to       
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 polymorphism and  
patient age at   
diagnosis  
Sabine 
Spiegl-Kreinecker 
younger patients (aged <65 years), while the negative        
prognostic power of enhanced age at diagnosis was        
limited to those patients lacking TERT promoter       
mutations. Presence of the common single nucleotide       
polymorphism rs2853669, disrupting an endogenous     
Ets2 transcription factor-binding site, was associated      
with improved survival exclusively in patients with a        
wild-type TERT promoter. On the contrary, the       
shortest mean overall survival was detected in those        
patients harbouring both an activating TERT promoter       
mutation and homozygous rs2853669 alleles. 
 
TERT mutation in   
glioma: Frequency,  
prognosis and risk  
Yang Yuan 
2016 Meta-analysis: ​Showed that the TERT gene is a        
valuable prognostic and predictive biomarker of      
glioma, and TERT gene polymorphisms are      
significantly associated with an increased risk of       
glioma. The study showed that a mutation in the TERT          
promoter is associated with a worse prognosis in        
patients with gliomas. 
 
TERT promoter  
mutations: a novel   
independent 
2014 The presence of ​TERT mutations was associated with        
poor overall survival, and the effect was confined to         
the patients who did not carry the variant G-allele for          
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 prognostic factor in   
primary 
glioblastomas  
Matthias Simon 
the rs2853669 polymorphism. An exploratory analysis      
suggested that ​TERT mutations might be prognostic       
only in patients who had incomplete resections and no         
temozolomide chemotherapy. 
Mutations in ​IDH1​,   
IDH2 ​, and in the    
TERT ​promoter  
define clinically  
distinct subgroups of   
adult malignant  
gliomas  
Patrick J. Killela 
2014 Mutations in the ​TERT promoter occurred in 74.2% of         
glioblastomas (GBM). Patients whose Grade III-IV      
gliomas exhibit ​TERT promoter mutations alone      
predominately have primary GBMs associated with      
poor median OS (11.5 months).  
Expression level of   
hTERT ​is regulated   
by somatic mutation   
and common single   
nucleotide 
polymorphism at  
promoter region in   
glioblastoma  
Chul-Kee Park 
2014 The somatic mutations of TERT promoter C228T and        
C250T were encountered in 60.4% of the GBMs and a          
single nucleotide polymorphism (T349C) in the      
hTERT promoter region was found in 66,6% of the         
GBMs. The somatic mutations were associated with a        
higher expression of TERT than the SNP T349C.        
There was no significant difference in the survival of         
the patients with the various types of mutations. 
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 TERT ​promoter  
mutations and long   
telomere length  
predict poor survival   
and radiotherapy  
resistance in gliomas  
Ke Gao 
215 Coexisting ​TERT promoter mutations and long      
telomere length were more commonly associated with       
poor patient survival than they were individually.  
Molecular Pathways  
in Gliomagenesis and   
Their Relevance to   
Neuropathologic 
Diagnosis  
Christina L. Appin 
2015 Primary GBMs typically lack IDH mutations and are        
instead characterized by EGFR, PTEN, TP53,      
PDGFRA, NF1, and CDKN2A/B alterations and      
TERT promoter mutations. Tumors without the IDH       
mutation were more aggressive and had a genetic        
profile more similar to glioblastomas. 
Upregulating 
mutations in the   
TERT ​promoter  
commonly occur in   
adult malignant  
gliomas and are   
strongly associated  
with total 1p19q loss 
2013 Found a high incidence of mutually exclusive       
mutations located at two hot spots, C228T and C250T,         
in all subtypes of gliomas (55 %). The expression level          
of ​TERT in tumors carrying those mutations was on         
average 6.1 times higher than that of wild-type tumors,         
indicating that the mutated promoter leads to       
upregulation of ​TERT​. ​TERT promoter mutations were       
observed in almost all tumors harboring concurrent       
total 1p19q loss and ​IDH1/2 mutations (98 %).        
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 Hideyuki Arita Otherwise ​TERT promoter mutations were mostly      
observed among ​IDH wild-type tumors. Most ​EGFR       
amplifications (92 %) were also associated with ​TERT        
promoter mutations.  
 
The prognostic  
impact of TERT   
promoter mutations  
in glioblastomas is   
modified by the   
rs2853669 single  
nucleotide 
polymorphism  
Rui Batista 
2016 The rs2853669 SNP, located in the TERT promoter        
region, is reported to modulate the increased TERT        
expression levels induced by the recurrent somatic       
mutations. TERT promoter mutations are a major       
indicator of poor survival in GBM, independently from        
other risk factors such as age and Karnofsky        
Performance Status. However, poor prognosis     
conferred by TERT promoter mutations was restricted       
to GBM patients carrying the rs2853669 A allele and         
not in those carrying the G allele. 
TERT Promoter  
Mutations Lead to   
High Transcriptional  
Activity under  
Hypoxia and  
Temozolomide 
Treatment and  
2014 TERT promoter mutations were specific to gliomas.       
TERT promoter mutations maintained its ability of       
inducing high transcriptional activity even under      
hypoxic and TMZ treatment conditions, and the       
presence of mutations was associated with poor       
prognosis in glioma patients. 
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 Predict Poor  
Prognosis in Gliomas  
Chen Chen 
Brain regions  
associated with  
telomerase reverse  
transcriptase 
promoter mutations  
in primary  
glioblastomas  
Xing Fan 
2016 TERT promoter mutations were detected in 46.3 % of         
the patients. GBMs with ​TERT promoter mutations       
were much more likely to locate in the right temporal          
lobe, while those with wild-type ​TERT promoters were        
more likely to occur in the anterior region of the right           
lateral ventricle. 
No significant difference was found in the lesion        
volumes of the tumor or in the contrast enhancement         
areas between the two groups.  
Also, the size of the peritumoral edema did not         
correlate to the mutation of the TERT promoter. 75.5%         
of the tumors that had the mutation also had a          
peritumoral edema larger than 1 cm, whereas 75.2% of         
the tumors without the mutation also showed had        
peritumoral edemas of similar size. 
Recurrent TERT  
promoter mutations  
identified in a large-    
2015 TERT promoter mutations were highly frequent in       
glioblastoma (83.9%). C228T and C250T were the       
most common mutations. ​TERT promoter mutations      
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 scale study of   
multiple tumour  
types are associated   
with increased TERT   
expression and  
telomerase activation  
Dong-Sheng Huang 
highly correlated with upregulated ​TERT mRNA      
expression and telomerase activity in adult gliomas.  
TERT promoter  
mutation designates  
biologically 
aggressive primary  
glioblastoma  
Jason T. Huse 
2014 Found a high rate of TERT mutations in their cohort          
(76.6%). Moreover, TERT mutations were much more       
common in primary versus secondary GBMs and were        
inversely correlated with ​IDH1/2 mutations. The      
largest subset of lower-grade gliomas harbors virtually       
no ​TERT mutations and is instead highly enriched in         
ATRX mutations and the alternative lengthening of       
telomeres (ALT) phenotype, a telomerase-independent     
telomere maintenance mechanism. 
 
TERT ​promoter  
mutated WHO  
grades II and III    
gliomas are located   
preferentially in the   
2015 Grades II and III gliomas harboring TERT promoter        
mutation were located preferentially in the frontal lobe        
and rarely in midline.  
Tumors in the frontal lobe presented more frequently a         
TERT promoter mutation. Mutations of the TERT       
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 frontal lobe and   
avoid the midline  
Ze-Lin Sun 
promoter combined with IDH mutations were more       
frequently found in the frontal lobe as well. In         
comparison, tumors in the midline had the least        
frequency of both TERT promoter mutations as well as         
the combination of TERT promoter mutations and IDH        
mutations. 
TERT promoter  
mutations occur  
frequently in gliomas   
and a subset of    
tumors derived from   
cells with low rates    
of self-renewal  
Patrick J. Killela 
2013 TERT-high tumor types almost always originated in       
tissues with relatively low rates of self-renewal.       
Mutations of the telomere binding proteins alpha       
thalassemia/mental retardation syndrome X-linked    
(ATRX) has been shown to underlie a telomere        
maintenance mechanism not involving telomerase.     
TERT and ATRX mutations were mutually exclusive,       
suggesting that these two genetic mechanisms confer       
equivalent selective growth advantages. 
Distribution of ​TERT   
promoter mutations  
in pediatric and adult    
tumors of the   
nervous system  
Christian Koelsche 
2013 TERT promoter mutations were strongly associated      
with older age.  
The highest frequency of mutations was found in        
gliosarcomas (81%), oligodendrogliomas (78%),    
primary glioblastomas (54%), and fibrous tumors      
(50%). 
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 TERT promoter mutations were strongly associated      
with 1p/19q loss but inversely associated with loss of         
ATRX expression and IDH1/IDH2 mutations. 
 
TERT promoter  
mutations in gliomas,   
genetic associations  
and 
clinico-pathological 
correlations  
M Labussie`re 
2014 TERT ​promoter mutation identified in 60.8% of       
gliomas was globally associated with poorer outcome,       
as well as a higher expression of TERT mRNA,         
whereas a SNP rs2853669 was associated with a lower         
expression of TERT mRNA. The mutation of ​CIC (a         
repressor of ETV1-5 belonging to the Ets/TCF family)        
was also associated with ​TERT​ mRNA upregulation. 
Highly prevalent  
TERT ​promoter  
mutations in bladder   
cancer and  
glioblastoma  
Xiaoli Liu 
2013 Found highly prevalent ​TERT promoter mutations in       
bladder cancer, bladder cancer cell lines and       
glioblastoma. C228T was far more common than       
C250T in all cases. The two mutations were mutually         
exclusive in glioblastomas. 
TERT ​promoter  
mutations could  
indicate poor  
2014 In tumors without mutation in the TERT promoter, an         
amplification in EGFR is associated with a worse        
outcome. A mutation in IDH1 meant a longer survival         
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 prognosis in  
glioblastoma  
Hemi Malkki 
only in tumors that did not have a mutation in the           
TERT promoter as well. 
TERT promoter  
mutations and  
rs2853669 
polymorphism: 
prognostic impact  
and interactions with   
common alterations  
in glioblastomas  
Umberto Nencha 
2015 TERT promoter mutation, but not SNP rs2853669       
status, was associated with older age (61.4 vs. 52.8         
years). The TERT promoter mutation was associated       
with EGFR amplification chromosome 10q loss,      
CDKN2A deletion and IDH wt. EGFR amplification       
was associated with a better outcome in TERT        
promoter mutated GBM, and a worse outcome in        
TERT promoter WT.  
Promoting a new   
brain tumor  
mutation: ​TERT  
promoter mutations  
in CNS tumors  
Zachary J. Reitman 
2013 Primary GBMs are known to have a high TERT         
activity, whereas in secondary GBMs this enzyme is        
rarely active. It was also noticed that a subgroup of the           
adults with primary GBMs who have telomerase       
activation do not have a mutation of the TERT         
promoter, raising the question of what other genetic or         
epigenetic mechanisms could be responsible for the       
activation of telomerase in these tumors. 
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 The TERT promoter   
mutation status and   
MGMT promoter  
methylation status,  
combined with  
dichotomized 
MRI-derived and  
clinical features,  
predict adult primary   
glioblastoma survival  
Jinhuan Wang 
2018 TERT promoter mutations were observed in 66.42% of        
primary GBMs in adults. MRI-detected necrosis is       
positively associated with the TERT promoter      
mutation status. 
The worst prognosis for survival was associated with        
TERT promoter mutation in combination with elevated       
peritumoral edema.  
Association of  
Telomerase Reverse  
Transcriptase 
Promoter Mutations  
with the Prognosis of    
Glioma Patients: a   
Meta-Analysis  
Xiaogang Wang 
2015 Meta-analysis of total 11 studies suggested that TERT        
promoter mutations were significantly associated with      
worse prognosis of patients with gliomas. 
In the article, a meta-analysis was conducted of 9         
articles, where it was concluded that the mutation were         
independently associated with a worse prognosis.  
In conclusion, the mutation of the TERT promoter is a          
promising biomarker for predicting the prognosis in       
patients with gliomas. 
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 Clinical 
Characteristics and  
Prognostic 
Significance of  
TERT Promoter  
Mutations in Cancer:   
A Cohort Study and    
a Meta-Analysis  
Ping Yuan 
2016 Mutation in the TERT promoter was in this        
meta-analysis associated with metastasis, a higher      
grade of glioma, and e higher risk of death. 
Elevated TERT  
Expression in  
TERT-Wildtype 
Adult Diffuse  
Gliomas: 
Histological 
Evaluation with a   
Novel 
TERT-Specific 
Antibody  
Kenta Masui 
2018 Found an unexpected increase in TERT expression in        
TERT​-wildtype as well as ​TERT​-mutated gliomas and       
in tumor vasculature. This suggest that TERT protein        
expression may be regulated by several mechanisms in        
addition to its promoter mutation. 
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 From this survey a systematic review was conducted with the objective of studying the              
relationship between mutations in the TERT promoter in high grade glioblastomas (WHO IV             
- glioblastomas) and the size of peritumoral edemas as a possible prognostic factor.  
 
Of the selected articles, 13 (46,6%) showed a shorter survival for patients with GBMs              
where mutations in the TERT promoter were present, and out of these, 2 articles showed a                
shorter survival for patients with the mutation independent of the site of the mutation (C228T               
or C250T). Only 2 articles (7,1%) showed that the status of TERT had no prognostic value. 
 
Moreover, 2 of the selected articles showed evidence of a shorter survival when TERT              
promoter mutations were present even when IDH was mutated as well. In the absence of               
TERT promoter mutations, the results diverge however. Jason T. Huse et al, show in their               
article “TERT promoter mutation designates biologically aggressive primary glioblastoma”         
that a mutation in IDH1/2 is associated with a worse prognosis in patients with GBMs, but                
Hemi Malkki et al., come to the opposite conclusion in their article “TERT promoter              
mutations could indicate poor prognosis in glioblastoma”, saying that the presence of a             
mutation in IDH1 and the absence of mutation in TERT promoter is related to longer survival. 
In 2 articles, the presence of both TERT promoter mutation and SNP of rs2853669 where               
the polymorphism is situated in the A allele, is associated with a worse prognosis. However,               
Umberto Nencha et al., in their article “TERT promoter mutations and rs2853669            
polymorphism: prognostic impact and interactions with common alterations in glioblastomas”          
show that there is no difference in survival in patients with polymorphism in the A or G allele,                  
independently of the status of the TERT promoter. 
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 As for any relationship between age and the mutation of TERT promoter, Sabine             
Spiegl-Kreinecker in the article “Prognostic quality of activating TERT promoter mutations in            
glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis”           
showed that the mutation of TERT promoter was more accurate as a prognostic biomarker in               
younger patients, below 65 years. Christian Koelsche et al., in their paper “Distribution of              
TERT promoter mutations in pediatric and adult tumors of the nervous system” as well as               
Umberto Nencha et al., in their paper “TERT promoter mutations and rs2853669            
polymorphism: prognostic impact and interactions with common alterations in glioblastomas”          
state that mutations in TERT promoter is strongly correlated with older age.  
There were also contradictions regarding the location of tumors with the highest            
presence of TERT promoter mutations. Xing Fan et al., in their study “Brain regions              
associated with telomerase reverse transcriptase promoter mutations in primary         
glioblastomas” found a higher presence of mutations in tumors located in the right temporal              
lobe, whereas Ze-Lin Sun et al., in their article “TERT promoter mutated WHO grades II and                
III gliomas are located preferentially in the frontal lobe and avoid the midline” found the               
mutation more present in tumors in the frontal lobe. 
As for the expression of TERT 2 articles found that both patients with and without a                
mutation of the TERT promoter had a higher expression of TERT.  
 
As for the results regarding the size of the peritumoral edema the were some contrary               
conclusions. In the article by Xing Fan et al., “Brain regions associated with telomerase              
reverse transcriptase promoter mutations in primary glioblastomas”, no relationship was          
found between the size of the edema and the presence of a mutation in the TERT promoter.                 
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 However, Chang Shu et al., in their article “The TERT promoter mutation status and MGMT               
promoter methylation status, combined with dichotomized MRI-derived and clinical features,          
predict adult primary glioblastoma survival”, did find such a relationship. Particularly when            
comparing tumors with and without a mutation in the TERT promoter, the peritumoral edema              
was twice as large in tumors with the mutation. Also, the results from the study show that a                  
lower rate of survival was found in patients with the mutation and a larger edema, and the                 
patients with the longest survival without the mutation were young patients. 
 
Finally, in the article by Chang Shu it is concluded that patients that showed the largest                
peritumoral edema on their MRI, and had a mutation in the TERT promoter, detected              
post-surgically in the biopsy of the tumor, were the ones with worst prognosis and had the                
highest mortality rate, as is shown in the figure below from Chang Shu’s article. 
 
Figure 1: Overall survival related to size of the peritumoral edema and mutation of the               
TERT promoter. 
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